What drug and pharmaceutical categories does Meta restrict?

Meta's Restricted Drugs and Pharmaceuticals policy covers a broad taxonomy of products that fall under healthcare or drug regulatory oversight in any major market. The restricted categories include prescription drugs where direct-to-consumer (DTC) advertising is subject to authorization; over-the-counter medications in jurisdictions where OTC advertising faces category-specific rules; online pharmacies and telehealth platforms that dispense or prescribe medication; weight loss and dietary supplement products that make health claims; smoking cessation products including nicotine replacement therapy and related devices; medical devices that require regulator clearance such as CGMs, hearing aids, and diagnostic tools; and compounded pharmaceuticals including compounded GLP-1 medications and other specialty compounds. The policy does not cover general wellness content or educational material about health topics, but the line between education and promotion is strict — any content that identifies a specific product, dosage, or purchase pathway enters restricted territory. Recent policy updates have added particular emphasis on compounded GLP-1 medications, telehealth-prescribed weight loss products, and online pharmacy aggregators, reflecting enforcement priorities in the 2025-2026 policy cycle. For broader healthcare advertising context, see our Healthcare Social Media Compliance guide .

What are the rules for direct-to-consumer prescription drug ads?

Direct-to-consumer prescription drug advertising on Meta is permitted only in jurisdictions where DTC pharmaceutical advertising is legal — principally the United States and New Zealand. Most other markets prohibit or severely restrict DTC prescription advertising, and Meta's policy enforces the restriction at the audience targeting level. In permitted jurisdictions, DTC prescription ads must comply with regulator-specific disclosure standards. In the United States, FDA regulations require prescription drug advertising to include a fair balance of efficacy and safety information, present material risks prominently, and comply with the brief summary or adequate provision requirements for risk disclosure. Meta layers platform-specific requirements on top of FDA compliance: the brand name must match the product registration, the indication must be consistent with the approved label, the creative must not overstate efficacy, and the creative must not minimize the risk information. Ads for products under enforcement actions, products withdrawn from the market, or products subject to FDA warning letters are prohibited regardless of platform targeting. For automated pre-flight checks on prescription creative, use our AI Compliance Audit .

How does Meta's policy treat online pharmacies and telehealth?

Online pharmacies and telehealth platforms face a dedicated authorization pathway under Meta's drugs and pharmaceuticals policy because they combine dispensing and prescribing activities with cross-border reach. Meta requires online pharmacy advertisers to hold the appropriate dispensing license or registration in each target jurisdiction and to complete the category-specific ad authorization process. In the United States, online pharmacies must typically be verified by programs such as the National Association of Boards of Pharmacy's Digital Pharmacy Accreditation (formerly the VIPPS program) or hold state-specific dispensing licenses for each state they serve. In the European Union, online pharmacies must be registered with the national regulator in each member state where they operate and display the EU common logo linking to the national register. In the United Kingdom, online pharmacies must be registered with the General Pharmaceutical Council and display the GPhC registration. Telehealth platforms face parallel requirements that depend on the specific services offered — platforms that only provide consultations face lighter restrictions than platforms that prescribe scheduled substances or high-risk medications. Ads promoting cross-border medication sourcing, unauthorized compounding, or products not permitted in the target jurisdiction are prohibited regardless of the platform's base jurisdiction.

Can weight loss drugs and compounded GLP-1 medications be advertised on Meta?

The policy treatment of weight loss drugs and compounded GLP-1 medications has evolved significantly through 2024, 2025, and into 2026 as the category exploded in consumer demand. FDA-approved weight loss prescription drugs (including the approved commercial GLP-1 products) can be advertised under the standard prescription drug DTC framework in permitted jurisdictions, subject to FDA fair balance and risk disclosure requirements and Meta's authorization process. Compounded GLP-1 medications face a substantially stricter framework. Meta's policy prohibits advertising of compounded medications in most circumstances, reflecting regulatory concerns about the compounded GLP-1 supply chain, FDA enforcement actions against certain telehealth-compounder partnerships, and ongoing litigation between branded manufacturers and compounding operators. Weight loss products marketed without FDA approval or other recognized regulatory status — including most supplement-style weight loss products and unauthorized compounded formulations — face blanket prohibition on Meta. Telehealth platforms promoting access to weight loss medication must specify the regulatory pathway of the advertised product, and creative cannot imply that users will automatically receive compounded or off-label formulations. For a policy snapshot on emerging compounded medication enforcement, see our Policy Change Tracker .

What disclosures are required for pharmaceutical ads on Meta?

Disclosure requirements for pharmaceutical advertising on Meta follow the regulatory framework of each target jurisdiction, layered on top of Meta's platform requirements. In the United States, FDA regulations require prescription drug DTC advertising to present the major risks of the product with appropriate prominence and to include either a brief summary of FDA-approved labeling or adequate provision for accessing the full labeling — on digital platforms, adequate provision is typically satisfied through links to the full prescribing information hosted on the product's website. Advertisers must also include the approved indication, generic name, and brand name consistently with the FDA label. OTC product advertising in the US must comply with general FTC advertising rules plus any product-category-specific labeling. In the European Union, the EU Medicines Directive imposes restrictions on DTC prescription advertising broadly and requires OTC advertising to include specific risk warnings and the statement that consumers should consult a healthcare professional. In the United Kingdom, the ABPI Code of Practice and MHRA rules govern pharmaceutical advertising. Meta's ad review checks for presence of required disclosures but not sufficiency under local regulatory standards. Advertisers should conduct regulatory-specific review of creative in parallel with Meta's ad review process. See our US Meta Compliance Guide for FDA-specific breakdowns.

What happens when a pharmaceutical ad is rejected on Meta?

Pharmaceutical ad rejections on Meta route through the Account Quality dashboard with specific failure codes that identify the triggering policy clause. The most frequent rejection categories are missing authorization, claims violations, targeting configuration, and landing page compliance gaps. For authorization failures, the remediation requires completing or updating the drugs and pharmaceuticals category authorization and submitting any missing regulatory evidence. For claims violations, the remediation requires identifying the specific language or imagery triggering the rejection — common culprits include overstated efficacy, minimized risk presentation, and unapproved indication references — and revising the creative with input from regulatory affairs. For targeting failures, the remediation requires adjusting audience targeting to match the authorization scope, excluding jurisdictions where the product lacks appropriate authorization. For landing page failures, the remediation requires updates to the destination page to include required disclosures, full prescribing information access, regulatory status, and any jurisdiction-specific required statements. Appeals submit through Account Quality; the SLA varies by advertiser status but typically runs 5 to 10 business days for new or unmanaged accounts. For pharmaceutical advertisers with high-stakes creative, pre-submission review via our Meta Rejection Predictor can surface likely rejection triggers before submission.

Meta Drug & Pharma Ads 2026: Prescription, OTC & Pharmacy

Meta Drug & Pharmaceutical Ads Policy 2026 — Prescription Rules, OTC Advertising & Pharmacy Authorization

Inside This Compliance Report

1Meta Drug & Pharmaceutical Policy Scope
2Prescription Drug DTC Advertising Rules
3OTC Medication Advertising Rules
4Online Pharmacy & Telehealth Authorization
5Weight Loss & Compounded Medication Enforcement
6Disclosure Framework by Jurisdiction
7Pharmaceutical Advertiser Compliance Checklist
8Frequently Asked Questions

Meta Drug & Pharmaceutical Policy Scope

Meta's Restricted Drugs and Pharmaceuticals policy covers any product that falls under healthcare or drug regulatory oversight in any major market where Meta serves ads. The policy applies to prescription drug advertising, over-the-counter medication advertising, online pharmacies, telehealth platforms, medical devices, compounded pharmaceuticals, and a range of adjacent categories where regulator attention has intensified in recent years.

The policy exists because pharmaceutical advertising creates elevated consumer safety risk, faces rigorous jurisdiction-specific regulation, and has historically been one of the most heavily enforced restricted categories across digital platforms. By gating pharmaceutical advertising behind category authorization and targeting restrictions, Meta creates an accountability structure that aligns platform enforcement with the underlying regulatory landscape.

"Ads for prescription drugs are only allowed with prior written permission from Meta and are restricted to certain countries. Online pharmacies must be certified and serve only jurisdictions where they hold appropriate dispensing authorization."
— Meta Advertising Standards, Drugs and Pharmaceuticals section

Prescription Drug DTC Advertising Rules

Direct-to-consumer prescription drug advertising is permitted on Meta only in jurisdictions where DTC prescription advertising is legal under local pharmaceutical regulation. The principal permitted markets are the United States and New Zealand, where DTC advertising is established practice. Most other jurisdictions prohibit or severely restrict DTC prescription advertising, and Meta enforces the restriction at the audience targeting level.

Key DTC Rules in Permitted Markets

Authorization required: Advertisers must complete Meta's drug and pharmaceutical authorization before ads can run.
Fair balance: Efficacy claims must be balanced by appropriate risk information presented with comparable prominence.
Brand and generic consistency: Both brand name and generic name must appear; the indication must match the approved label.
Approved indication only: Off-label promotion is prohibited; creative must reference only approved indications.
Risk presentation: Material risks must be disclosed with prominence comparable to efficacy claims.
Adequate provision: On digital platforms, adequate provision for full prescribing information is typically satisfied through a link to the full labeling.
No promotion of withdrawn or warning-letter products: Products under FDA enforcement or withdrawn from market cannot be advertised.

For a complete breakdown of US pharmaceutical advertising compliance, see our US Meta Compliance Guide.

OTC Medication Advertising Rules

Over-the-counter medication advertising is permitted in most major markets, but each jurisdiction applies category-specific rules that Meta enforces through a combination of automated review and manual verification.

Jurisdiction	Primary Regulator	Key Requirements
United States	FDA, FTC	Truthful and not misleading; substantiated claims; label-consistent messaging
European Union	EMA, national regulators	Risk warnings and advice to consult healthcare professional required
United Kingdom	MHRA	Marketing authorization required; ABPI Code compliance for certain categories
Canada	Health Canada	DIN or NPN required; compliance with Canadian marketing guidelines
Australia	TGA	Therapeutic Goods Advertising Code compliance; restricted representations rules

OTC categories that face additional scrutiny include pain relief products (restrictions on efficacy comparisons), allergy and respiratory products (requirements around sponsored claims), and smoking cessation products (additional disclosure and age targeting).

Online Pharmacy & Telehealth Authorization

Online pharmacies and telehealth platforms face dedicated authorization requirements because they combine dispensing and prescribing activities with cross-border reach. Meta's authorization process for these advertisers is the most rigorous in the pharmaceutical category.

Online Pharmacy Authorization Steps

Dispensing license verification: Advertiser submits dispensing license documentation for each jurisdiction it serves.
Certification program evidence: Where applicable, evidence of accreditation under a recognized program (such as the US Digital Pharmacy Accreditation) or listing on a national register.
Cross-border operations review: Meta reviews any cross-border dispensing activity against source and destination jurisdiction rules.
Product catalog review: Advertisers disclose product categories offered and demonstrate authorization for controlled substances, prescription drugs, and OTC products separately.
Landing page audit: Destination pages are reviewed for regulatory status display, verification emblems, and compliant purchase flows.

Telehealth Platform Rules

Consultation-only platforms face lighter restrictions than platforms that prescribe medication.
Platforms that prescribe controlled substances face additional restrictions and often require managed-account relationships.
Weight loss-focused telehealth platforms face category-specific scrutiny around compounded medication access.
Creative cannot imply guaranteed prescription outcomes from a consultation.

For a full healthcare advertising framework, see our Healthcare Social Media Compliance guide.

Weight Loss & Compounded Medication Enforcement

The weight loss category has been the most dynamic subcategory in Meta's drug and pharmaceutical policy through 2025 and into 2026, driven by consumer demand for GLP-1 medications, rapid growth in telehealth-compounder partnerships, and regulatory enforcement actions against aspects of the compounded supply chain.

Current Policy Posture

FDA-approved branded GLP-1 products can be advertised under the standard prescription drug DTC framework in permitted jurisdictions, subject to fair balance and risk disclosure.
Compounded GLP-1 medications face prohibition in most advertising contexts, reflecting regulatory concerns about the compounded supply chain.
Supplement-style weight loss products marketed without FDA approval face blanket prohibition on Meta when they make weight loss efficacy claims.
Telehealth platforms offering weight loss consultations must specify the regulatory pathway of any mentioned product and cannot imply guaranteed access to compounded formulations.

Enforcement in this subcategory is among the most active in Meta's restricted categories, with automated detection trained specifically on weight loss creative patterns. Advertisers in the weight loss space should expect elevated review times and build regulatory review buffers into launch schedules.

Disclosure Framework by Jurisdiction

United States (FDA): Fair balance; brand and generic name; approved indication; major risks; adequate provision for full prescribing information.
European Union: DTC prescription prohibited broadly; OTC requires risk warnings and advice to consult a healthcare professional.
United Kingdom: MHRA marketing authorization reference; ABPI Code compliance for prescribing-influencing content.
Canada: Name, indication, and risk information; adequate provision rules for digital platforms.
Australia (TGA): Therapeutic Goods Advertising Code compliance; restricted representation rules; prohibition on certain claims without regulator approval.

Disclosure sufficiency is the advertiser's responsibility. Meta's ad review verifies presence of required elements but does not certify that disclosures meet local regulatory standards. Parallel regulatory review should be conducted for every pharmaceutical creative before submission.

Pharmaceutical Advertiser Compliance Checklist

[ ] Drug and pharmaceutical category authorization obtained
[ ] License or marketing authorization documented for each target jurisdiction
[ ] Product category mapping (Rx, OTC, device, compounded, supplement) completed
[ ] Targeting restricted to authorized jurisdictions
[ ] Creative includes fair balance (for Rx in permitted markets)
[ ] Brand and generic names consistent with approved label
[ ] Only approved indication referenced; no off-label promotion
[ ] Risk information presented with appropriate prominence
[ ] Adequate provision for full prescribing information (via link to labeling page)
[ ] Landing page includes required disclosures and regulatory status
[ ] Online pharmacy accreditation displayed where applicable
[ ] Weight loss creative reviewed against compounded-medication restrictions
[ ] Parallel regulatory review of creative completed
[ ] Rejection response protocol documented

Monitor Meta's pharmaceutical policy evolution via our Policy Change Tracker.

Don't miss the next policy change.

Subscribe to the Policy Change Tracker — get weekly digests or instant Pro alerts across all 8 platforms. Or try our free Keyword Risk Checker first.

Subscribe Free

Report Keywords — Run AI Compliance Audit

#Meta Ads#Pharmaceutical Ads#Prescription Drugs#OTC Advertising#Pharmacy#Healthcare Compliance#DTC Pharma#Platform Policy#Meta Policy 2026#FDA#Restricted Categories#Healthcare Advertising

Share This Report

Tweet Share

Meta Drug & Pharmaceutical Ads Policy 2026 — Prescription Rules, OTC Advertising & Pharmacy Authorization

Inside This Compliance Report

Meta Drug & Pharmaceutical Policy Scope

Prescription Drug DTC Advertising Rules

Key DTC Rules in Permitted Markets

OTC Medication Advertising Rules

Online Pharmacy & Telehealth Authorization

Online Pharmacy Authorization Steps

Telehealth Platform Rules

Weight Loss & Compounded Medication Enforcement

Current Policy Posture

Disclosure Framework by Jurisdiction

Pharmaceutical Advertiser Compliance Checklist

Don't miss the next policy change.

Report Keywords — Run AI Compliance Audit

Share This Report

Related Posts

Meta Health & Wellness Restricted Ads 2026 — Supplements, Body Image & Medical Claim Rules

Germany HWG Law: How to Advertise Supplements on Meta Without Getting Banned

Meta Restricted Financial Services Ads Policy 2026 — Country Licensing, Authorization & Disclosure Rules

Related Resources

All Tools

Platform Guides

Knowledge Hub

Policy Tracker